VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

VANCOUVER - In a significant development for its proprietary small molecule drug candidates, InMed Pharmaceuticals Inc. (NASDAQ: INM), a $3.6 million market cap pharmaceutical company dedicated to ...

InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It operates through the InMed Pharma and BayMedica segments. The InMed Pharma segment is organized around the ...

INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in neurodegeneration marker, neurofilament ...

Vancouver, British Columbia--(Newsfile Corp. - January 22, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of ...

This page features the latest news about the InMed Pharmaceuticals stock. InMed Pharmaceuticals Reports Results from Phase 2 Trial in Epidermolysis Bullosa InMed Pharmaceuticals Inc.

InMed Pharmaceuticals shares are trading higher by 45% during Tuesday's session. The company announced that INM-901 reduced Alzheimer 's-related inflammation in a preclinical study.

InMed Pharmaceuticals ( NASDAQ:INM ) Second Quarter 2025 Results Key Financial Results Revenue: US$1.11m (down 10% from... Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed ...